ImmuCell/$ICCC
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About ImmuCell
ImmuCell Corp is engaged in the healthcare sector. The company operates in the development, acquisition, manufacture, and sale of products that improve the health and productivity of cows for the dairy and beef industries. The company operates in two business segment. The Scours segment is dedicated to manufacturing and selling First Defense, a product used to prevent scours in newborn calves, which is regulated by the United States Department of Agriculture (USDA). The Mastitis segment is focused on developing and commercializing Re-Tain, a product to treat subclinical mastitis in lactating dairy cows, which is regulated by the United States Food and Drug Administration (FDA). The company generates the majority of its revenue from the Scours segment.
Ticker
$ICCC
Sector
Primary listing
Employees
81
Headquarters
Website
ImmuCell Metrics
BasicAdvanced
$55M
23.40
$0.26
0.19
-
Price and volume
Market cap
$55M
Beta
0.19
52-week high
$7.60
52-week low
$4.28
Average daily volume
19K
Financial strength
Current ratio
4.209
Quick ratio
1.625
Long term debt to equity
40.037
Total debt to equity
45.655
Interest coverage (TTM)
5.23%
Profitability
EBITDA (TTM)
5.433
Gross margin (TTM)
42.40%
Net profit margin (TTM)
8.37%
Operating margin (TTM)
9.85%
Effective tax rate (TTM)
0.61%
Revenue per employee (TTM)
$340,000
Management effectiveness
Return on assets (TTM)
3.79%
Return on equity (TTM)
8.27%
Valuation
Price to earnings (TTM)
23.395
Price to revenue (TTM)
1.958
Price to book
1.83
Price to tangible book (TTM)
1.84
Price to free cash flow (TTM)
75.996
Free cash flow yield (TTM)
1.32%
Free cash flow per share (TTM)
0.079
Growth
Revenue change (TTM)
16.49%
Earnings per share change (TTM)
-152.75%
3-year revenue growth (CAGR)
11.37%
10-year revenue growth (CAGR)
11.05%
3-year earnings per share growth (CAGR)
37.03%
10-year earnings per share growth (CAGR)
-2.48%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for ImmuCell stock?
ImmuCell (ICCC) has a market cap of $55M as of December 17, 2025.
What is the P/E ratio for ImmuCell stock?
The price to earnings (P/E) ratio for ImmuCell (ICCC) stock is 23.4 as of December 17, 2025.
Does ImmuCell stock pay dividends?
No, ImmuCell (ICCC) stock does not pay dividends to its shareholders as of December 17, 2025.
When is the next ImmuCell dividend payment date?
ImmuCell (ICCC) stock does not pay dividends to its shareholders.
What is the beta indicator for ImmuCell?
ImmuCell (ICCC) has a beta rating of 0.19. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.